Swiss drug manufacturer Roche has become the latest pharma company to seek revenues in the treatment of liver diseases such as non-alcoholic steatohepatitis (NASH). Roche is acquiring Switzerland-based Jecure Therapeutics, which is developing NLRP3 inhibitors to treat inflammatory diseases such as NASH. Rival firms Pfizer and Novartis recently partnered to work on NASH treatments, while Gilead Sciences has also entered the sector.
Swiss drug manufacturer Roche has become the latest pharma company to seek revenues in the treatment of liver diseases such as non-alcoholic steatohepatitis (NASH). Roche is acquiring US-based Jecure Therapeutics, which is developing NLRP3 inhibitors to treat inflammatory diseases such as NASH. Rival firms Pfizer and Novartis recently partnered to work on NASH treatments, while Gilead Sciences has also entered the sector.